Skip to main content
Premium Trial:

Request an Annual Quote

Europroteome, Abbott Collaborate on Breast Cancer Diagnostics Development

NEW YORK, March 1 (GenomeWeb News) - Abbott Laboratories has entered a research collaboration with Europroteome to discover and develop in vitro diagnostic tests for the early detection of breast cancer, the companies said today.


Under the deal, Europroteome will use its proteomics and bioinformatics technologies to analyze serum samples from women with breast cancer. The resultant data will be aligned with a panel of cancer markers from Abbott. Combinations of markers will be selected for further development and integration into Abbott's instrument platforms, the companies said.


Abbott will pay Europroteome an upfront fee, as well as milestone payments. Abbott will also have an option for a royalty-bearing license to the results from the research collaboration, and well be responsible for commercial assay development and marketing.


The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.